| Document |
Document Title |
|
WO/2016/055681A1 |
The invention relates to the processing and use of fluids of the reproductive tract (biofluids) for improving the in vitro production of embryos of mammals, comprising the following steps: fractionating and processing the biofluids by me...
|
|
WO/2016/054741A1 |
The invention relates to a microsphere composition comprising (a) a microsphere material; and (b) a lipidic liquid formulation comprising (i) an effective amount of a progestogen, and (ii) vitamin E or an analog of vitamin E, incorporate...
|
|
WO/2016/056001A1 |
The present invention relates to a composition for intravaginal and/or for internal mucosal application, comprising an effective amount of a sulfated polysaccharide, one or more of a natural quaternary polymer, a quaternary molecular com...
|
|
WO/2016/052573A1 |
[Problem] The objective of the present invention is to provide a formulation technique with which hardening of a capsule coating over time can be suppressed in a capsule that is formed by filling contents, which include an anthocyanin, a...
|
|
WO/2016/053092A1 |
The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: ∙ 1-100 wt.% of particles consisting of: - 0.01-10wt.% of a partus contro...
|
|
WO/2016/042451A1 |
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein f...
|
|
WO/2016/041255A1 |
A traditional Chinese medicine composition capable of enriching yin, nourishing kidney and nourishing qi. The formula comprises the following ingredients: 5 to 15 g of codonopsis pilosula, 8 to 15 g of black soyabean coats, 15 to 25 g of...
|
|
WO/2016/044447A1 |
There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorder...
|
|
WO/2016/038308A1 |
The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
|
|
WO/2016/038309A1 |
The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.
|
|
WO/2016/038310A1 |
The present invention relates to an antibody against the follicle-stimulating hormone (FSH), said antibody being capable of potentializing FSH and CG bioactivity.
|
|
WO/2016/037424A1 |
A medicinal liquor and a preparation method therefor. The medicinal liquor is characterized by being prepared with the following raw materials: codonopsis pilosula, black soybean coat, date, rhizoma polygonatum, dried tangerine peel, spa...
|
|
WO/2016/036093A1 |
The present disclosure relates to compositions for preparing an oral dispersible film comprising tadalafil or its pharmaceutically acceptable salt thereof, surfactant, plasticizer and sweetening agent; an oral dispersible film; and metho...
|
|
WO/2016/030901A1 |
The present invention relates to compositions and methods for preventing premature follicle activation and loss induced by acute insults, such as, medical treatment, a disease or a disorder, thereby preserving fertility in a subject.
|
|
WO/2016/033287A1 |
The present disclosure relates to methods of collecting cervical-vaginal fluid exosomes and microvesicles and isolating corresponding mRNA. In particular, certain embodiments relate to the method of collecting the cervical-vaginal fluids...
|
|
WO/2016/031987A1 |
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)
|
|
WO/2016/028971A1 |
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inven...
|
|
WO/2016/028045A1 |
The present invention relates to a veterinary composition for prevention and treatment of sterility using a mixed herbal extract, an animal feed additive, and a feed comprising the same. Morinda officinalis How, Cuscutae Semen and/or an ...
|
|
WO/2016/027228A1 |
A pharmaceutical composition or dietary supplement with antioxidant activity, mood- regulating activity and insulin-sensitizing activity, with a consequent reduction of the accumulation of adipose tissue, is described, for use in the pre...
|
|
WO/2016/028979A1 |
Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) a...
|
|
WO/2016/026772A1 |
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein X1 is selected from C and N; X3 and X5 may be the...
|
|
WO/2016/028225A1 |
The present invention relates to platinum compounds of Formula (I) or (II) as defined herein as well as their use for the treatment of cancer, methods for treating cancer in a subject using said compounds, and methods for triggering apop...
|
|
WO/2016/026474A1 |
The present invention provides new strains of lactobacilli, producing substances effective against vaginal pathogens, Lactobacillus crispatus CCM 7997; Lactobacillus reuteri CCM 7998; Lactobacillus crispatus CCM 8522; Lactobacillus ferme...
|
|
WO/2016/025541A1 |
The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of curcuminoid containing compositi...
|
|
WO/2016/025669A1 |
The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic...
|
|
WO/2016/021508A1 |
The present invention provides an epitope peptide derived from CDCA1 and having a cytotoxic T-cell induction ability. The present invention also provides: a polynucleotide for coding the peptide; an antigen-presenting cell presenting the...
|
|
WO/2016/003327A9 |
The use of 3-(3-[1,2,4]-triazolo)-oxatriazolium-5-olate for treating sexual disorders. The invention relates to the chemical and pharmaceutical industry, and more particularly to the creation of a novel agent for treating sexual disorder...
|
|
WO/2016/009377A1 |
The present invention relates to a free parietal fraction of Propionibacterium acnes and granulosum, obtained by delipidation and controlled crushing of the strain ATCC51277 or DSM20458. Said free fraction is particularly useful as an im...
|
|
WO/2016/008282A1 |
Disclosed is a use of berberine in the preparation of drugs for treating ovulatory dysfunction infertility. The berberine induces ovulation of a patient, and reduces the probability of a multiple pregnancy, pregnancy complications and ad...
|
|
WO/2016/008039A1 |
The present invention provides microbicidal compositions comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof, and methods of using the compositions for the prevention of conception and/or prevention of trans...
|
|
WO/2016/006260A1 |
Provided is an ex vivo medium for causing normal progress to the blastocyst stage without stopping development in the ex vivo culture of fertilized eggs. The normal development rate of fertilized eggs is improved by using 5-aminolevulini...
|
|
WO/2016/003122A1 |
The present invention relates to a complex composition having enhanced efficacy and safety for treating or alleviating dysmenorrhea. More particularly, the present invention relates to a complex composition for treating or alleviating dy...
|
|
WO/2016/001350A1 |
The invention relates to a method for providing regular contraception to a woman. Said method comprises administering a daily contraceptive amount of ulipristal acetate or a metabolite thereof over a period of at least 21 consecutive days.
|
|
WO/2015/196759A1 |
Disclosed are pyrazole compounds, and pharmaceuticaly acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
|
|
WO/2015/198054A1 |
Described herein are new treatments for the pain associated with endometriosis. More particularly, there is provided a novel combination of at least one SCN11Aantagonistand at least one SCN11Aexpression level modifier for use in the trea...
|
|
WO/2015/196335A1 |
Pyrazole compounds useful as positive allosteric modulators of follicle stimulating hormone receptor and pharmaceutically acceptable compositions thereof are provided.
|
|
WO/2015/193228A1 |
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...
|
|
WO/2015/193219A1 |
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and...
|
|
WO/2015/193217A1 |
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, 3,4-dihydropyrido[2,3-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, an...
|
|
WO/2015/193229A1 |
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...
|
|
WO/2015/186056A1 |
The invention relates to compounds of formula (I) Formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-c...
|
|
WO/2015/185499A1 |
A 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbon
itrile compound of the formula (I) wherein R1 is -COCH2R2, COO-C1-6-alkyl, CH2CONR3R4, pyridinyl, pyrimidinyl or C1-6-alkyl which is optionally substituted with C1-6-alkoxy, ...
|
|
WO/2015/173693A1 |
The present invention relates to a new composition, containing boric acid and a mixture of at least two lactobacilli selected from L. rhamnosus, L. crispatus, L. jensenii and L. gasseri. The present invention further relates to the use o...
|
|
WO/2015/172400A1 |
A pharmaceutical composition for treating infertility, comprising the following raw materials: 10-20 parts by weight of radix rehmanniae preparata, 10-20 parts by weight of radix paeoniae alba, 10-20 parts by weight of cornus officinalis...
|
|
WO/2015/173666A1 |
The present invention refers to a composition comprising as active ingredients Rhodiola and folic acid for use in the treatment of premature ejaculation Moreover, the present invention also relates to said composition in the form of a ph...
|
|
WO/2015/172399A1 |
A pharmaceutical composition for improving male reproductive system functions. The composition is prepared using 4-6 parts by weight of fructus lycii, 2-4 parts by weight of semen cuscutae, 1.5-3.5 parts by weight of fructus rubi, 1-2 pa...
|
|
WO/2015/174439A1 |
The present invention provides an antigen-binding molecule that exhibits an excellent antitumor effect greater than exhibited by conventional antigen-binding molecules, as a result of the antigen-binding molecule: cross-linking T cells a...
|
|
WO/2015/174636A1 |
The present invention relates to a composition and health functional food for preventing and treating male infertility using a mixed herbal mixture. Through an in vitro sperm mobility promotion effect evaluation method experiment for inv...
|
|
WO/2015/174481A1 |
An agent that is for the prevention and treatment of chlamydia infection, that is highly safe and can be administered over an extended period of time, and that has Lactobacillus casei as an active ingredient.
|
|
WO/2015/170122A1 |
The present invention relates to a CRH formulation and to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.
|
